mortality/aging
N |
• mice injected with Tg(TcraTcrb)1100Mjb CD8+ T cells from a Rag1 null mouse and anti-ovalbumin IgG survive unlike of similarly treated Tg(Ins2-TFRC/OVA)296Wehi mice
|
immune system
• proliferation of Tg(TcraTcrb)1100Mjb CD8+ T cells from a Rag1 null mouse in the presence or absence of anti-ovalbumin IgG is enhanced compared to in similarly treated Tg(Ins2-TFRC/OVA)296Wehi mice
|
• mice treated with Tg(TcraTcrb)1100Mjb CD8+ T cells from a Rag1 null mouse alone exhibit higher a incidence of insulitis than of similarly treated Tg(Ins2-TFRC/OVA)296Wehi and Tg(Ins2-TFRC/OVA)296Wehi Fcer1gtm1Rav/Fcer1gtm1Rav mice
|
• mice treated with Tg(TcraTcrb)1100Mjb CD8+ T cells from a Rag1 null mouse without anti-ovalbumin IgG exhibit an IFN-gamma production that is increased 3-fold compared to in similarly treated Tg(Ins2-TFRC/OVA)296Wehi mice
|
• only 40% of mice treated with Tg(TcraTcrb)1100Mjb CD8+ T cells from a Rag1 null mouse and anti-ovalbumin IgG exhibit diabetes compared to 100% of similarly treated Tg(Ins2-TFRC/OVA)296Wehi mice
• the severity of diabetes induced by Tg(TcraTcrb)1100Mjb CD8+ T cells and anti-ovalbumin IgG is reduced compared to in similarly treated Tg(Ins2-TFRC/OVA)296Wehi mice
|
endocrine/exocrine glands
• mice treated with Tg(TcraTcrb)1100Mjb CD8+ T cells from a Rag1 null mouse alone exhibit higher a incidence of insulitis than of similarly treated Tg(Ins2-TFRC/OVA)296Wehi and Tg(Ins2-TFRC/OVA)296Wehi Fcer1gtm1Rav/Fcer1gtm1Rav mice
|
hematopoietic system
• proliferation of Tg(TcraTcrb)1100Mjb CD8+ T cells from a Rag1 null mouse in the presence or absence of anti-ovalbumin IgG is enhanced compared to in similarly treated Tg(Ins2-TFRC/OVA)296Wehi mice
|
cellular
• proliferation of Tg(TcraTcrb)1100Mjb CD8+ T cells from a Rag1 null mouse in the presence or absence of anti-ovalbumin IgG is enhanced compared to in similarly treated Tg(Ins2-TFRC/OVA)296Wehi mice
|